RGX 202- REGENXBIO
Alternative Names: RGX-202 - REGENXBIOLatest Information Update: 07 Aug 2024
At a glance
- Originator REGENXBIO
- Class Gene therapies
- Mechanism of Action Dystrophin replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Duchenne muscular dystrophy
Most Recent Events
- 02 Aug 2024 Updated pharmacodynamics data from a phase I/II AFFINITY DUCHENNE trial in Duchenne Muscular Dystrophy released by REGENXBIO
- 01 Aug 2024 REGENXBIO completes an end-of-Phase II (EOP2) meeting with the US FDA for Duchenne muscular dystrophy
- 01 Aug 2024 REGENXBIO plans to initiate a pivotal dose determination trial for Duchenne muscular dystrophy in the second half of 2024